Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00053118
Recruitment Status : Completed
First Posted : January 28, 2003
Last Update Posted : March 1, 2011
Information provided by:
Roswell Park Cancer Institute

January 27, 2003
January 28, 2003
March 1, 2011
March 2002
July 2004   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00053118 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
High Dose Carboplatin Combined With Oral VP-16 In The Treatment Of Pediatric CNS Malignancies

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining chemotherapy with peripheral stem cell transplantation in treating children who have central nervous system cancer.


  • Determine the feasibility of administering an outpatient protocol comprising high-dose carboplatin with autologous stem cell support and etoposide in pediatric patients with primary central nervous system malignancies.
  • Determine the maximum tolerated dose of carboplatin when administered in this regimen in these patients.
  • Determine the toxicity of this regimen in these patients.

OUTLINE: This is dose-escalation study of carboplatin.

Patients receive filgrastim (G-CSF) IV once daily for 6 days followed by a maximum of 5 apheresis sessions. If the target number of peripheral blood stem cells is not achieved, some patients receive G-CSF and undergo apheresis as above after a 2-week rest.

At least 3 days after completion of G-CSF, patients receive high-dose carboplatin IV over 1 hour on day 1, stem cell reinfusion on day 3, G-CSF subcutaneously on days 4-18 and 43-61, and oral etoposide 3 times daily on days 21-42. Treatment continues for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of carboplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed monthly for 1 year and then annually thereafter.

PROJECTED ACCRUAL: A total of 3-15 patients will be accrued for this study.

Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Brain and Central Nervous System Tumors
  • Lymphoma
  • Neuroblastoma
  • Retinoblastoma
  • Biological: filgrastim
  • Drug: carboplatin
  • Drug: etoposide
  • Procedure: bone marrow ablation with stem cell support
  • Procedure: peripheral blood stem cell transplantation
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
July 2004
July 2004   (Final data collection date for primary outcome measure)


  • Histologically confirmed primary central nervous system malignancy
  • Recurrent, persistent, or progressive disease after at least 1 prior first-line treatment regimen



  • 18 and under at initial diagnosis

Performance status

  • ECOG 0-2

Life expectancy

  • At least 8 weeks


  • Absolute neutrophil count greater than 750/mm^3
  • WBC greater than 2,500/mm^3
  • Platelet count greater than 100,000/mm^3
  • No underlying myelodysplasia, stem cell disorder, or other inherent hematologic synthetic defect


  • Liver function tests less than 2 times normal OR
  • Absence of active hepatitis by liver biopsy
  • Bilirubin less than 1.5 mg/dL


  • Glomerular filtration rate greater than 60 mL/min by radionucleotide assay


  • Ejection fraction at least 45%


  • Clinically normal pulmonary function (patients 5 years of age and under)
  • FEV_1 and FVC at least 50% (patients over 5 years of age) OR
  • Arterial blood gas normal and DLCO greater than 50%


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No mucositis or mucosal infection
  • HIV negative


Biologic therapy

  • Not specified


  • At least 3 weeks since prior systemic cytotoxic chemotherapy

Endocrine therapy

  • Not specified


  • At least 6 months since prior radiotherapy to the pelvis or spine


  • Not specified
Sexes Eligible for Study: All
up to 18 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Barbara Bambach, MD, Roswell Park Cancer Institute
Roswell Park Cancer Institute
Not Provided
Study Chair: Barbara Jean Bambach, MD Roswell Park Cancer Institute
Roswell Park Cancer Institute
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP